FDA advisers narrowly backed Galleri, a blood test that aims to detect more than 50 cancers before symptoms appear.

The 10-member panel voted 6-4 that the test is effective and 7-2, with one abstention, that benefits outweigh risks.

Made by Grail, Galleri looks for fragments of DNA in the blood that may signal cancer.

Grail says it identifies the likely tissue of origin with 93.4% accuracy.

It has been sold in the US since 2021 without FDA approval for nearly $1,000, for adults 50 and older.

An NHS trial of over 140,000 people missed its main goal, though it showed 26% fewer stage IV diagnoses.

Experts warn of false positives causing anxiety and false negatives giving false reassurance.

The panel vote is not FDA approval, which is still pending, and Grail says the test should not replace standard screenings.

Read the full article for more details on the Galleri cancer blood test.